The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

References

• Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 378(6555), 386–390 (1995).
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Plenker D, Osada H et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 4(4), 415–422 (2014).
   PubMed Web of Science ®Google Scholar
• Dhanasekaran SM, Balbin OA, Chen G et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat. Commun. 5, 5893 (2014).
   PubMed Web of Science ®Google Scholar
• Werr L, Plenker D, Dammert MA et al. CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Mol. Cancer. Ther. 21(5), 821–830 (2022).
   PubMed Web of Science ®Google Scholar
• Chang JC, Offin M, Falcon C et al. Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes. Clin. Cancer. Res. 27(14), 4066–4076 (2021).
   PubMed Web of Science ®Google Scholar
• Jonna S, Feldman RA, Swensen J et al. Detection of NRG1 gene fusions in solid tumors. Clin. Cancer. Res. 25(16), 4966–4972 (2019).
   PubMed Web of Science ®Google Scholar
• Jones MR, Williamson LM, Topham JT et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin. Cancer. Res. 25(15), 4674–4681 (2019).
   PubMed Web of Science ®Google Scholar
• Murayama T, Nakaoku T, Enari M et al. Oncogenic fusion gene CD74-NRG1 confers cancer stem cell-like properties in lung cancer through a IGF2 autocrine/paracrine circuit. Cancer Res. 76(4), 974–983 (2016).
   PubMed Web of Science ®Google Scholar
• Laskin J, Liu SV, Tolba K et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann. Oncol. 31(12), 1693–1703 (2020).
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Ou SI. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends. Cancer. 8(3), 242–258 (2022).
   PubMed Web of Science ®Google Scholar
• Benayed R, Offin M, Mullaney K et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer. Res. 25(15), 4712–4722 (2019).
   PubMed Web of Science ®Google Scholar
• Drilon A, Duruisseaux M, Han JY et al. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry. J. Clin. Oncol. 39(25), 2791–2802 (2021).
   PubMed Web of Science ®Google Scholar
• Geuijen CAW, De Nardis C, Maussang D et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer. Cell. 33(5), 922–936 (2018).
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Pace EA, Fitzgerald JB et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor–PI3K axis. Sci. Signal. 2(77), ra31 (2009).
   PubMed Web of Science ®Google Scholar
• Thakkar D, Sancenon V, Taguiam MM et al. 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models. Mol. Cancer. Ther. 19(2), 490–501 (2020).
   PubMed Web of Science ®Google Scholar
• Nakaoku T, Tsuta K, Ichikawa H et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin. Cancer. Res. 20(12), 3087–3093 (2014).
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Mangatt BP et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer. Discov. 8(6), 686–695 (2018).
   PubMed Web of Science ®Google Scholar
• Rosas D, Raez LE, Russo A, Rolfo C. Neuregulin 1 gene (NRG1). A potentially new targetable alteration for the treatment of lung cancer. Cancers (Basel). 13(20), 5038 (2021).
   PubMed Web of Science ®Google Scholar
• Schram AM, O'Reilly EM, O'Kane GM et al. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions. J. Clin. Oncol. 39(Suppl. 15), 3003 (2021).
   Google Scholar
• Liu SV, Feldman RA, Borghaei H et al. Incidence of neuregulin1 (NRG1) gene fusions across tumor types. J. Clin. Oncol. 36(Suppl. 15), 12084 (2018).
   Web of Science ®Google Scholar
• Heining C, Horak P, Uhrig S et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer. Discov. 8(9), 1087–1095 (2018).
   PubMed Web of Science ®Google Scholar
• Knepper TC, Kim DW, Mauer E et al. Comparative analysis of the targetable landscape in KRAS-mutant and wild-type pancreatic adenocarcinoma. J. Clin. Oncol. 40(Suppl. 16), 4155 (2022).
   Web of Science ®Google Scholar
• Philip PA, Xiu J, Hall MJ et al. Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC). J. Clin. Oncol. 38(Suppl. 15), 4629 (2020).
   Web of Science ®Google Scholar
• Jones MR, Lim H, Shen Y et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann. Oncol. 28(12), 3092–3097 (2017).
   PubMed Web of Science ®Google Scholar
• Schram AM, Odintsov I, Espinosa-Cotton M et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer. Discov. 12(5), 1233–1247 (2022).
   PubMed Web of Science ®Google Scholar
• Gerlach J, Odintsov I, Schackmann R et al. Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions. Presented at: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Mol. Cancer. Ther. 20(Suppl. 12), P201 (2021).
   Google Scholar
• Geuijen CAW, De Nardis C, Maussang D et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer Cell 33(5), 922–936 (2018).
   PubMed Web of Science ®Google Scholar